首页> 美国卫生研究院文献>BMC Cancer >A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy

【2h】

A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy

机译：接受一线靶向治疗的转移性肾细胞癌患者意外延长或缩短无进展生存期和总体生存期的预测因素的回顾性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundTo identify predictors of prolonged or shortened progression-free survival (PFS) and overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC) who received first-line targeted therapies.

机译：背景为了确定接受一线靶向治疗的转移性肾细胞癌（mRCC）患者中无进展生存期（PFS）和总生存期（OS）延长或缩短的预测因素。

著录项

期刊名称 BMC Cancer
作者
Sung Han Kim; Sohee Kim; Jungnam Joo; Ho Kyung Seo; Jae Young Joung; Kang Hyun Lee; Jinsoo Chung;
展开▼
作者单位

展开▼
年(卷),期 2016(16),-1
年度 2016
页码 577
总页数 11
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Renal cell carcinoma Neoplasm metastasis Prognosis Overall survival Progression free survival Molecular targeted therapy;

机译：肾细胞癌;肿瘤转移;预后;总生存期;无进展生存期;分子靶向治疗;

相似文献

外文文献
中文文献
专利

1. A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy [J] . Sung Han Kim, Sohee Kim, Jungnam Joo, BMC Cancer . 2016,第1期

机译：接受一线靶向治疗的转移性肾细胞癌患者意外延长或缩短无进展生存期和总体生存期的预测因素的回顾性研究
2. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. [J] . Patil S, Figlin RA, Hutson TE, Annals of oncology: official journal of the European Society for Medical Oncology . 2011,第2期

机译：舒尼替尼靶向治疗和以细胞因子为一线治疗的转移性肾细胞癌患者无进展生存和总体生存的预后因素。
3. Survival and clinical prognostic factors in metastatic non‐clear cell renal cell carcinoma treated with targeted therapy: A multi‐institutional, retrospective study using the Korean metastatic renal cell carcinoma registry [J] . Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Cancer Medicine . 2019,第7期

机译：靶向治疗治疗的转移性非透明细胞肾细胞癌的生存和临床预后因素：使用韩国转移性肾细胞癌登记系统的多机构回顾性研究
4. Computational Pathology Analysis of TissueMicroarrays Predicts Survival of Renal Clear Cell Carcinoma Patients [C] . Thomas J. Fuchs, Peter J. Wild, Holger Moch, International Conference on Medical Image Computing and Computer-Assisted Intervention;MICCAI 2008 . 2008

机译：组织芯片的计算病理分析预测肾透明细胞癌患者的生存。
5. Analysis of prognostic factors for the development of metastases and survival in renal cell carcinoma patients [D] . Cheng, Jed-Sian 2008

机译：肾细胞癌患者转移和存活的预后因素分析
6. A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy [O] . Sung Han Kim, Yoon Seok Suh, Dong-Eun Lee, 2017

机译：VEGF靶向治疗中低危患者异时和同步转移性肾细胞癌无进展生存期和总生存期的回顾性比较研究
7. A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy [O] . 2016

机译：接受一线靶向治疗的转移性肾细胞癌患者意外延长或缩短无进展生存期和总体生存期的预测因素的回顾性研究

A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy

摘要

著录项

相似文献

相关主题

期刊订阅